Stock listing
NASDAQ:OBIO Orchestra BioMed Holdings, Inc. Stock
Home listing (NASDAQ) of Orchestra BioMed Holdings, Inc.
Follow Orchestra BioMed Holdings, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:OBIO
$6.58 USD -0.88 (-11.8%)
Close on Nov 20, 2026
- Day range
- $6.47 – $7.14 USDNov 20, 2026
- Volume
- 554,315 sharesNov 20, 2026
- Market cap
- $517.9M USDAt the close on Nov 20, 2026 · price × 78.70M shares outstanding
- 52-week range
- $3.46 – $7.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.48M USDMedian day 284,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:OBIO · Home | $6.58 USD | -0.88 (-11.8%) | 554,315 | $6.89 | $7.14 | $6.47 | $7.46 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.58 | -0.88 | -11.8% | $6.89 | $7.14 | $6.47 | 554,315 | |
| $7.46 | +0.49 | +7.0% | $7.02 | $7.825 | $7.00 | 1,203,905 | |
| $6.97 | -0.15 | -2.1% | $7.10 | $7.365 | $6.95 | 551,845 | |
| $7.12 | -0.13 | -1.8% | $7.16 | $7.45 | $7.04 | 755,454 | |
| $7.25 | +1.10 | +17.9% | $6.25 | $7.365 | $6.00 | 1,564,544 | |
| $6.15 | +0.14 | +2.3% | $6.08 | $6.18 | $5.70 | 631,014 | |
| $6.01 | +0.28 | +4.9% | $5.75 | $6.34 | $5.73 | 452,902 | |
| $5.73 | +0.03 | +0.5% | $5.83 | $5.90 | $5.69 | 485,538 | |
| $5.70 | +0.02 | +0.4% | $5.73 | $5.88 | $5.36 | 781,799 | |
| $5.68 | +0.06 | +1.1% | $5.135 | $6.04 | $5.135 | 1,740,882 | |
| $5.62 | -0.38 | -6.3% | $6.00 | $6.00 | $5.60 | 253,745 | |
| $6.00 | +0.44 | +7.9% | $5.815 | $6.161 | $5.78 | 335,412 | |
| $5.56 | -0.13 | -2.3% | $5.70 | $5.98 | $5.52 | 273,209 | |
| $5.69 | -0.22 | -3.7% | $5.92 | $6.02 | $5.66 | 317,495 | |
| $5.91 | -0.18 | -3.0% | $6.07 | $6.075 | $5.845 | 231,581 | |
| $6.09 | +0.10 | +1.7% | $6.05 | $6.16 | $6.00 | 274,563 | |
| $5.99 | +0.21 | +3.6% | $5.76 | $6.03 | $5.685 | 427,145 | |
| $5.78 | +0.23 | +4.1% | $5.842 | $5.842 | $5.52 | 376,769 | |
| $5.55 | -0.04 | -0.7% | $5.58 | $5.655 | $5.52 | 242,656 | |
| $5.59 | +0.12 | +2.2% | $5.46 | $5.66 | $5.39 | 262,000 | |
| $5.47 | -0.335 | -5.8% | $5.72 | $5.789 | $5.43 | 390,900 | |
| $5.805 | -0.015 | -0.3% | $5.83 | $5.865 | $5.57 | 486,000 | |
| $5.82 | +0.17 | +3.0% | $5.65 | $6.17 | $5.53 | 992,100 | |
| $5.65 | +0.20 | +3.7% | $5.49 | $5.73 | $5.415 | 226,600 | |
| $5.45 | -0.29 | -5.1% | $5.75 | $5.87 | $5.37 | 473,700 | |
| $5.74 | +0.10 | +1.8% | $5.68 | $5.85 | $5.66 | 253,400 | |
| $5.64 | -0.08 | -1.4% | $5.70 | $5.86 | $5.60 | 222,900 | |
| $5.72 | -0.19 | -3.2% | $5.87 | $5.87 | $5.71 | 204,800 | |
| $5.91 | -0.04 | -0.7% | $5.93 | $5.99 | $5.39 | 237,900 | |
| $5.95 | +0.22 | +3.8% | $5.73 | $5.965 | $5.56 | 229,300 | |
| $5.73 | +0.07 | +1.2% | $5.75 | $5.83 | $5.51 | 241,900 | |
| $5.66 | -0.18 | -3.1% | $5.79 | $5.859 | $5.64 | 241,200 | |
| $5.84 | -0.19 | -3.2% | $6.05 | $6.12 | $5.82 | 213,100 | |
| $6.03 | +0.08 | +1.3% | $5.89 | $6.09 | $5.79 | 284,800 | |
| $5.95 | -0.40 | -6.3% | $6.40 | $6.44 | $5.77 | 421,100 | |
| $6.35 | +0.13 | +2.1% | $6.27 | $6.50 | $6.23 | 389,900 | |
| $6.22 | +0.14 | +2.3% | $6.09 | $6.29 | $6.00 | 270,700 | |
| $6.08 | +0.19 | +3.2% | $5.89 | $6.09 | $5.83 | 237,100 | |
| $5.89 | -0.06 | -1.0% | $5.95 | $5.95 | $5.80 | 177,500 | |
| $5.95 | 0.00 | 0.0% | $5.99 | $6.17 | $5.86 | 248,800 | |
| $5.95 | +0.02 | +0.3% | $5.90 | $6.05 | $5.75 | 262,900 | |
| $5.93 | -0.29 | -4.7% | $6.10 | $6.20 | $5.90 | 242,300 | |
| $6.22 | -0.03 | -0.5% | $6.15 | $6.48 | $6.053 | 342,900 | |
| $6.25 | +0.17 | +2.8% | $6.04 | $6.29 | $5.85 | 433,200 | |
| $6.08 | +0.30 | +5.2% | $5.74 | $6.30 | $5.71 | 1,137,400 | |
| $5.78 | -0.23 | -3.8% | $6.03 | $6.26 | $5.73 | 411,200 | |
| $6.01 | -0.03 | -0.5% | $6.05 | $6.28 | $5.93 | 297,200 | |
| $6.04 | +0.14 | +2.4% | $6.00 | $6.13 | $5.93 | 228,400 | |
| $5.90 | -0.22 | -3.6% | $6.07 | $6.20 | $5.74 | 383,500 | |
| $6.12 | +0.31 | +5.3% | $5.87 | $6.25 | $5.76 | 464,400 | |
| $5.81 | +0.36 | +6.6% | $5.845 | $6.08 | $5.68 | 761,500 | |
| $5.45 | +0.02 | +0.4% | $5.31 | $5.46 | $5.261 | 198,600 | |
| $5.43 | +0.35 | +6.9% | $5.18 | $5.51 | $4.80 | 359,300 | |
| $5.08 | +0.34 | +7.2% | $4.71 | $5.14 | $4.71 | 478,100 | |
| $4.74 | -0.21 | -4.2% | $4.97 | $4.97 | $4.71 | 325,600 | |
| $4.95 | +0.05 | +1.0% | $4.92 | $5.01 | $4.83 | 240,400 | |
| $4.90 | -0.14 | -2.8% | $5.02 | $5.349 | $4.875 | 214,500 | |
| $5.04 | -0.145 | -2.8% | $5.23 | $5.33 | $5.004 | 276,600 | |
| $5.185 | +0.075 | +1.5% | $5.23 | $5.23 | $5.06 | 154,500 | |
| $5.11 | -0.15 | -2.9% | $5.23 | $5.42 | $5.10 | 220,500 | |
| $5.26 | -0.10 | -1.9% | $5.36 | $5.45 | $5.16 | 391,700 | |
| $5.36 | -0.08 | -1.5% | $5.37 | $5.50 | $5.35 | 169,600 | |
| $5.44 | +0.08 | +1.5% | $5.35 | $5.48 | $5.21 | 249,500 | |
| $5.36 | -0.07 | -1.3% | $5.45 | $5.53 | $5.27 | 276,700 | |
| $5.43 | -0.12 | -2.2% | $5.53 | $5.58 | $5.38 | 209,600 |
- Ticker
- NASDAQ:OBIO
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 30 slides
Latest news
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
Nov 17, 2026
Closed $6.97 (-2.1%) on Nov 17, 2026
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Nov 10, 2026
Closed $6.01 (+4.9%) on Nov 11, 2026
Orchestra BioMed Announces Pricing of Public Offering
Nov 5, 2026
Closed $5.68 (+1.1%) on Nov 6, 2026
Orchestra BioMed Announces Proposed Public Offering
Nov 5, 2026
Closed $5.68 (+1.1%) on Nov 6, 2026
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Oct 29, 2026
Closed $6.09 (+1.7%) on Oct 29, 2026
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Oct 22, 2026
Closed $5.47 (-5.8%) on Oct 22, 2026
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
Oct 1, 2026
Closed $6.35 (+2.1%) on Oct 1, 2026
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Sep 16, 2026
Closed $6.01 (-0.5%) on Sep 16, 2026
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Sep 15, 2026
Closed $6.04 (+2.4%) on Sep 15, 2026
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Aug 27, 2026
Closed $5.11 (-2.9%) on Aug 27, 2026
Orchestra BioMed Holdings, Inc. on 6ix
- News releases
- 24 in the last 12 months · 82 in all · newest Nov 17, 2026 · oldest 2022
- Decks
- 21 decks · latest October 2026
Where Orchestra BioMed Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:OBIO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:OBIO | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $417.1M USD
- P/E
- Loss
- EV/sales
- 13.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 66.5×
- Gross margin
- 99.4%
- Operating margin
- −195.4%
- Net margin
- −182.5%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.59
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.43 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.52 · 6 analysts
- Revenue, year to Dec 2026
- 451.1K · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David P. Hochman | Chairman, Chief Executive Officer |
| Andrew Taylor | Chief Financial Officer |
| Darren R. Sherman | President, Chief Operations Officer, Director |
| Amy Berman | Vice President, Clinical Operations |
| Avi Fischer | Senior Vice President, Medical Affairs and Innovation |
| Bill Little | Executive Vice President, Corporate Development and Strategy |
| Bob Laughner | Senior Vice President of Regulatory and Quality |
| Hans-Peter Stoll | Senior Vice President, Medical Director |
| Heather Buckley | Vice President, Marketing |
| John Sieckhaus | Vice President, Global Field Clinical Engineering |
| Juan Lorenzo | Senior Vice President of Product Development |
| Kunal Faldu | Vice President, Pharmaceutical Development, Focal Therapies |
| Lisa Daniels | Vice President, Human Resources |
| Mark Pomeranz | Executive Vice President and General Manager, Interventional Therapies |
| William Baumbach | Vice President, Scientific Affairs, Focal Therapies |
| Ziv Belsky | Vice President, Research & Development, Bioelectronic Therapies |
| Yuval Mika | General Manager and Chief Technology Officer, Bioelectronic Therapies |
Board
| Director | Role |
|---|---|
| David P. Hochman | Chairman, Chief Executive Officer |
| Chris Cleary | Board Member |
| Darren R. Sherman | President, Chief Operations Officer, Director |
| David Pacitti | Board Member |
| Eric Fain | Chair of the Compensation Committee |
| Jason Aryeh | Chair of the Nominating and Corporate Governance Committee |
| John Mack | Board Member |
| Pamela Connealy | Board Member, Audit Committee Chair |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +4.9% |
| Q2 2026 | Aug 10, 2026 · After close | −1.4% |
| Q1 2026 | May 13, 2026 | +1.2% |
| Q4 2025 | Mar 12, 2026 · Before open | −4.8% |
| Q3 2025 | Nov 10, 2025 · After close | +8.5% |
| Q2 2025 | Aug 12, 2025 · Before open | +7.9% |
| Q1 2025 | May 12, 2025 · After close | +10.9% |
| Q4 2024 | Mar 31, 2025 | −26.4% |
| Q3 2024 | Nov 12, 2024 · After close | +7.2% |
| Q2 2024 | Aug 12, 2024 · After close | −2.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | +13.0% |
| Q4 2023 | Mar 27, 2024 · After close | −0.7% |
| Q3 2023 | Nov 13, 2023 · After close | +13.1% |
| Q2 2023 | Aug 10, 2023 · After close | −1.6% |
| Q1 2023 | May 12, 2023 · Before open | 0.0% |
| Q4 2022 | Jan 25, 2023 | +30.5% |
| Q3 2022 | Dec 16, 2022 · After close | +0.5% |
| Q2 2022 | Aug 15, 2022 | 0.0% |
| Q1 2022 | May 13, 2022 | +0.1% |
| Q4 2021 | Mar 31, 2022 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 30 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 26 slides | Sep 8, 2026 |
| Technical Presentation (2026) | Technical | 12 slides | 2026 |
| CRT 2026 | Conference | 13 slides | 2026 |
| Corporate Update (November 2025) | Corporate update | 17 slides | Nov 13, 2025 |
| Investor Presentation (October 2025) | Investor deck | 24 slides | Oct 30, 2025 |
| Investor Presentation (March 2025) | Investor deck | 28 slides | Mar 3, 2025 |
| THT 2025 | Conference | 13 slides | 2025 |
| Investor Day (June 2024) | Investor day | 57 slides | Jun 11, 2024 |
| Investor Day (June 2024) | Investor day | 56 slides | Jun 11, 2024 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2024) | Investor deck | 23 slides | Mar 7, 2024 |
| Investor Presentation (November 2023) | Investor deck | 22 slides | Nov 14, 2023 |
| Investor Presentation (October 2023) | Investor deck | 21 slides | Oct 10, 2023 |
| Investor Presentation (September 2023) | Investor deck | 11 slides | September 2023 |
| Investor Presentation (July 2023) | Investor deck | 21 slides | Jul 13, 2023 |
| Investor Presentation (July 2023) | Investor deck | 21 slides | Jul 12, 2023 |
| Investor Presentation (June 2023) | Investor deck | 26 slides | Jun 8, 2023 |
| Investor Presentation (March 2023) | Investor deck | 27 slides | Mar 13, 2023 |
| Health Sciences Acquisitions Corp 2 — SPAC Merger (December 2022) | SPAC merger | 34 slides | Dec 1, 2022 |
| Health Sciences Acquisitions Corp 2 — SPAC Merger (July 2022) | SPAC merger | 32 slides | Jul 5, 2022 |
| Technical Presentation | Technical | 19 slides |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock Closed: US$80.5M raised · US$5 a share · Piper Sandler +3 Dealers: Piper Sandler (co-lead), TD Cowen (co-lead), BTIG, H.C. Wainwright & Co. Use of proceeds: Fund AVIM Therapy program and BACKBEAT Trial, Virtue SAB program and Virtue Trial, other R&D, working capital and general corporate purposes | Nov 10, 2026 |
| Public offering of shares of common stock Announced: Piper Sandler +2 Dealers: Piper Sandler (co-lead), TD Cowen (co-lead), BTIG Use of proceeds: Fund AVIM Therapy program and BACKBEAT trial, Virtue SAB program and Virtue Trial, other R&D, working capital and general corporate purposes | Nov 5, 2026 |
| Strategic investment of strategic capital Closed: US$35M raised Buyers: Medtronic (Medtronic's total capital contribution to Orchestra BioMed is nearly $82 million, including this investment); Ligand (Ligand has now provided $40 million in total capital to the Company) | Aug 10, 2026 |
| Strategic investment of non-voting convertible preferred stock Announced: US$20M Buyers: Terumo ($20 million in a new series of non-voting preferred stock) Use of proceeds: Advance both pivotal stage programs to key clinical and regulatory milestones | Oct 28, 2025 |
| Public offering of common stock and pre-funded warrants Announced: about US$40M · US$2.75 a share · Piper Sandler +1 Dealers: Piper Sandler (co-lead), TD Cowen (co-lead) Use of proceeds: Fund AVIM therapy program and BACKBEAT study, Virtue SAB program and trial, other product candidates, working capital and general corporate purposes | Aug 1, 2025 |
| Tiered royalty on future sales of AVIM therapy and Virtue SAB Announced: US$35M Buyers: Ligand ($20 million at closing and an additional $15 million at the nine-month anniversary, subject to conditions) Use of proceeds: To advance its late-stage partnered cardiology programs (AVIM therapy and Virtue SAB) | Jul 31, 2025 |
| Private placement of common stock Announced: US$5M Buyers: Ligand ($5 million of common stock) | Jul 31, 2025 |
| Private placement of common stock Announced: US$10M Buyers: Medtronic ($10 million of common stock) | Jul 31, 2025 |
| Secured subordinated promissory note convertible to prepaid revenue share Announced: US$20M Buyers: Medtronic ($20 million secured subordinated promissory note) | Jul 31, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Health Sciences Acquisitions Corp 2, a blank check company (SPAC). Priced at US$10.00 a share on Aug 3, 2020.
- Price
- US$10.00 a share
- Shares offered
- 13,913,044 ordinary shares
- Offering size
- US$139.1 million
- Underwriters' option
- Up to 2,086,956 more shares
- Listing
- HSAQ on the Nasdaq Capital Market
- Underwriters
- Chardan, Barclays · In the order on the cover
- Shares delivered
- On or about Aug 3, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 22, 2020 |
| Filed publicly | Jul 17, 2020 |
| Amended twice | Newest Jul 28, 2020 |
| Shares registered with an exchange | Aug 3, 2020 |
| Declared effective by the SEC | Aug 3, 2020 |
| Final prospectus, with the price | Aug 5, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 5, 2020 |
| CERT · Exchange's certificate of listing | Aug 4, 2020 |
| EFFECT · Notice that a registration is effective | Aug 3, 2020 |
| S-1MEF · Registration of more shares for the same offering | Aug 3, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 3, 2020 |
| CORRESP · Letter to the SEC | Jul 30, 2020 |
| CORRESP · Letter to the SEC | Jul 30, 2020 |
| S-1/A · Registration statement, amended | Jul 28, 2020 |
| S-1/A · Registration statement, amended | Jul 24, 2020 |
| S-1 · Registration statement | Jul 17, 2020 |
All 11 filings
| Filing | Filed |
|---|---|
| DRS · Draft registration statement | Jun 22, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 5, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 33.5M | 2.64M | 2.76M | 3.53M | -782.0K | 5.70M |
| Cost of revenue | 190.0K | 204.0K | 186.0K | 211.0K | 199.0K | 145.0K |
| Gross profit | 33.3M | 2.43M | 2.57M | 3.21M | -981.0K | 5.56M |
| Research and development | 58.2M | 42.8M | 33.8M | 21.9M | 12.9M | 13.5M |
| Selling, general and administrative | 26.9M | 23.9M | 20.3M | 14.0M | 7.93M | 10.8M |
| Operating income | -51.8M | -64.3M | -51.5M | -32.7M | -394.8K | -18.8M |
| Depreciation and amortization | 327.0K | 308.0K | 287.0K | 222.0K | 181.0K | 137.0K |
| EBITDA | -51.5M | -64.0M | -51.2M | -32.4M | -213.8K | -18.6M |
| Interest expense | 1.15M | 297.0K | 1.40M | 1.30M | 927.0K | |
| Income before tax | -52.7M | -61.0M | -49.1M | -33.6M | -23.0M | -21.4M |
| Income tax | 0 | 119.1K | -222.0K | 927.0K | 2.60M | |
| Net income | -52.7M | -61.0M | -49.1M | -33.6M | -378.8K | -21.4M |
| Earnings per share, basic | -1.11 | -1.66 | -1.48 | -2.24 | -0.02 | -1.04 |
| Earnings per share, diluted | -1.11 | -1.66 | -1.48 | -2.24 | -0.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 34.7M | 22.3M | 30.6M | 19.8M | 1.75M | 20.3M |
| Short-term investments | 71.8M | 44.6M | 57.0M | 63.9M | 958.0K | 15.4M |
| Receivables | 95.0K | 92.0K | 99.0K | 96.0K | 121.0K | 168.0K |
| Inventory | 310.0K | 173.0K | 146.0K | 276.0K | 68.0K | 69.0K |
| Current assets | 107.9M | 69.2M | 89.1M | 84.7M | 1.80M | 36.3M |
| Property, plant and equipment | 1.72M | 1.38M | 1.28M | 1.49M | 1.12M | 1.03M |
| Total assets | 114.9M | 76.2M | 95.2M | 95.6M | 161.8M | 38.1M |
| Accounts payable | 6.09M | 5.13M | 2.90M | 3.97M | 1.39K | 1.77M |
| Current liabilities | 16.7M | 16.2M | 11.2M | 18.6M | 165.5K | 14.4M |
| Long-term debt | 14.3M | 14.3M | 9.49M | 3.67M | 5.46M | |
| Total debt | 15.0M | 15.0M | 1.69M | 11.9M | 5.67M | 9.46M |
| Total liabilities | 51.5M | 43.2M | 27.2M | 43.0M | 5.77M | 86.6M |
| Shareholders' equity | 53.6M | 33.0M | 68.0M | 52.5M | -19.8M | -48.5M |
| Shares outstanding | 57.0M | 38.2M | 35.8M | 20.2M | 4.45M | 20.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -49.0M | -50.6M | -46.1M | -29.3M | -272.4K | -26.2M |
| Capital spending | -489.0K | -289.0K | -78.0K | -591.0K | -274.0K | -539.0K |
| Free cash flow | -49.5M | -50.8M | -46.2M | -29.9M | -19.7M | -26.7M |
| Cash from investing | -26.9M | 13.1M | 10.7M | -64.1M | 13.0M | 27.0M |
| Cash from financing | 88.3M | 29.2M | 46.2M | 103.3M | -3.99M | 10.0M |
| Share buybacks | -92.6M | |||||
| Change in cash | 12.4M | -8.30M | 10.8M | 9.85M | -272.4K | 10.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 9, 2026 | Material contract | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B5 · Prospectus | Nov 6, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Nov 5, 2026 | Offer document | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Meeting outcome | SEC |
| S-8 · Registration statement for employee plans | Jun 23, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Jun 15, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 25, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 13, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 21, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| S-3 · Registration statement | Oct 31, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| 8-K · Current report | Oct 28, 2025 | Material contract | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 1, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jul 31, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 31, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 24, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| 8-K · Current report | Feb 25, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Feb 19, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 5, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 23, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 6, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 6, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| 424B5 · Prospectus | Aug 12, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 7, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 30, 2024 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jul 30, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 17, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 11, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
This page holds 200 of 423 filings. Open Filings
Cap table
Built by 6ix from Orchestra BioMed Holdings, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 78,704,957
- Fully diluted
- 78,704,957
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 78,704,957 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 78,704,957 |
| Nov 9, 2026 | 95,954,957 |
| Nov 9, 2026 | 78,704,957 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jason M. Aryeh Other companies: Lifecore Biomedical, Inc. (Director · Since at least Aug 15, 2024); Anebulo Pharmaceuticals, Inc. (Board Member · Since at least May 6, 2021); Ligand Pharmaceuticals Incorporated (Director · Since at least May 30, 2007); Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 19, 2017 · Past); Novelion Therapeutics Inc (Director · Jun 4, 2012 – May 15, 2017 · Past); Myrexis Inc (Director · Oct 19, 2011 – Jun 18, 2012 · Past); Vaxart, Inc. (Director · May 18, 2007 – May 25, 2011 · Past) | Director · Since at least Jan 26, 2023 |
| Pedro P Granadillo Other companies: Rocket Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2018); Immunovant, Inc. (Director · May 9, 2019 – May 9, 2019 · Past); NPS Pharmaceuticals Inc (Director · Nov 17, 2010 – Feb 21, 2015 · Past); Dendreon Corp (Director · Oct 7, 2009 – Jan 3, 2014 · Past); Capricor Therapeutics, Inc. (Director · Oct 16, 2007 – May 10, 2011 · Past); Haemonetics Corporation (Director · May 5, 2006 – Nov 8, 2018 · Past); First Indiana Corp (Director · Jan 3, 2006 – Jan 2, 2008 · Past) | Director · Aug 3, 2020 – Aug 3, 2020 · Past |
| Carsten Boess Other companies: Atrium Therapeutics, Inc. (Director · Since at least Nov 10, 2025); Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Rocket Pharmaceuticals, Inc. (Director · Since at least Jan 11, 2016); Synageva BioPharma Corp (SVP, Chief Financial Officer · Nov 2, 2011 – Jun 22, 2015 · Past); Insulet Corporation (Vice President, International · May 14, 2007 – Apr 25, 2011 · Past) | Director · Aug 3, 2020 – Aug 3, 2020 · Past |
| Eric A Md Rose Other companies: ABIOMED Inc (Director · May 30, 2007 – Aug 10, 2022 · Past); SIGA Technologies Inc. (Director · Dec 19, 2006 – Jun 15, 2021 · Past); Keryx Biopharmaceuticals Inc (Director · Mar 14, 2006 – Nov 14, 2008 · Past); Nephros, Inc. (Director · Feb 2, 2006 – Jun 10, 2009 · Past) | Director · Jan 26, 2023 – Jun 20, 2024 · Past |
| David P. Hochman Other companies: Motus GI Holdings, Inc. (Director · Feb 13, 2018 – Feb 13, 2019 · Past); Corbus Pharmaceuticals Holdings, Inc. (Director · Nov 10, 2017 – May 20, 2020 · Past) | See Remarks, Director · Since at least Jan 26, 2023 |
| Naveen Yalamanchi Other companies: Immunovant, Inc. (Vice President and CFO, Director · May 9, 2019 – May 9, 2019 · Past); Rocket Pharmaceuticals, Inc. (Director · Jan 4, 2018 – Jun 13, 2024 · Past) | Chief Financial Officer, Director · Aug 3, 2020 – Aug 3, 2020 · Past |
| Alice Lee Other companies: Immunovant, Inc. (VPO, Secretary and Treasurer · May 9, 2019 – May 9, 2019 · Past) | VP Operations, Sec & Treasurer · Aug 3, 2020 – Aug 4, 2020 · Past |
| Andrew Taylor Other companies: Motus GI Holdings, Inc. (Chief Financial Officer · Feb 13, 2018 – Feb 10, 2022 · Past) | Chief Financial Officer · Since at least Jun 6, 2023 |
| Darren R. Sherman Other companies: Motus GI Holdings, Inc. (Director · Oct 12, 2020 – Feb 10, 2022 · Past) | See Remarks, Director · Since at least Jan 26, 2023 |
| David Pacitti Other companies: Avanos Medical, Inc. (Chief Executive Officer · Since at least Mar 17, 2025) | Director · Since at least Jun 23, 2026 |
All 35 people
| Person | Seat |
|---|---|
| Mark Pomeranz Other companies: Motus GI Holdings, Inc. (President and COO, Director · Feb 13, 2018 – Feb 10, 2022 · Past) | Executive Vice President and General Manager, Interventional Therapies · Since at least Nov 4, 2026 |
| Stephanie A Sirota Other companies: Immunovant, Inc. (VP of CSC · May 9, 2019 – May 9, 2019 · Past) | VP of Corp Stratege and Comm · Aug 3, 2020 – Aug 4, 2020 · Past |
| Amy Berman | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| Avi Fischer | Senior Vice President, Medical Affairs and Innovation · Since at least Oct 22, 2026 |
| Bill Little | Executive Vice President, Corporate Development and Strategy · Since at least Nov 4, 2026 |
| Bob Laughner | Senior Vice President of Regulatory and Quality · Since at least Nov 4, 2026 |
| Chris Cleary | Director · Since at least Jan 30, 2025 |
| Chris Cleary | Board Member · Since at least Aug 14, 2026 |
| Eric Fain | Director · Since at least Jan 26, 2023 |
| Geoffrey Wade Smith | Director · Jan 26, 2023 – Jul 20, 2023 · Past |
| George Papandreou | See Remarks · Sep 19, 2023 – May 8, 2024 · Past |
| Hans-Peter Stoll | Senior Vice President, Medical Director · Since at least Nov 4, 2026 |
| Heather Buckley | Vice President, Marketing · Since at least Nov 4, 2026 |
| John Mack | Director · Since at least Jul 29, 2024 |
| John Sieckhaus | Vice President, Global Field Clinical Engineering · Since at least Nov 4, 2026 |
| Joshua Aiello | Principal Accounting Officer · Since at least Jan 26, 2023 |
| Juan Lorenzo | Senior Vice President of Product Development · Since at least Nov 4, 2026 |
| Kunal Faldu | Vice President, Pharmaceutical Development, Focal Therapies · Since at least Nov 4, 2026 |
| Lisa Daniels | Vice President, Human Resources · Since at least Nov 4, 2026 |
| Michael Kaswan | Chief Financial Officer · Jan 26, 2023 – Apr 12, 2023 · Past |
| Pamela Connealy | Director · Since at least Jun 23, 2026 |
| William Baumbach | Vice President, Scientific Affairs, Focal Therapies · Since at least Nov 4, 2026 |
| William Reed Little | See Remarks · Jun 1, 2023 – May 30, 2024 · Past |
| Yuval Mika | General Manager and Chief Technology Officer, Bioelectronic Therapies · Since at least Aug 26, 2025 |
| Ziv Belsky | Vice President, Research & Development, Bioelectronic Therapies · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Orchestra BioMed Holdings, Inc.